Tranexamic Acid Administration in Traumatic Bleeding

Core Trial Findings

The CRASH-2 trial established that tranexamic acid (TXA) administered as a 1g loading dose over 10 minutes followed by 1g infusion over 8 hours significantly reduces all-cause mortality (14.5% vs 16.0%, RR 0.91) and bleeding deaths (4.9% vs 5.7%, RR 0.85) in trauma patients with significant hemorrhage, with maximum benefit when given within 3 hours of injury 1
All-cause mortality decreased from 16.0% to 14.5% with TXA treatment (relative risk 0.91, 95% CI 0.85-0.97, P=0.0035) 1
Death due to bleeding specifically decreased from 5.7% to 4.9% (relative risk 0.85, 95% CI 0.76-0.96, P=0.0077) 1

Treatment within 1 hour produced the greatest mortality reduction (5.3% vs 7.7% bleeding deaths; RR 0.68, 95% CI 0.57-0.82, P<0.0001) 1
Effectiveness decreases by 10% for every 15-minute delay in administration 2
Treatment between 1-3 hours still reduced bleeding deaths (4.8% vs 6.1%; RR 0.79, 95% CI 0.64-0.97, P=0.03) 1
Treatment after 3 hours INCREASED the risk of death due to bleeding (4.4% vs 3.1%; RR 1.44, 95% CI 1.12-1.84, P=0.004) 1
TXA should not be administered more than 3 hours following injury 1

The evidence-based dosing regimen from CRASH-2 is: Loading dose: 1g IV over 10 minutes 1
Maintenance infusion: 1g IV over 8 hours 1
This achieves therapeutic plasma levels of 10 μg/ml necessary to inhibit systemic fibrinolysis, with a plasma half-life of 120 minutes 1

No increase in thrombotic events - in fact, myocardial infarction rates were lower with TXA 1
Higher doses (beyond CRASH-2 protocol) are associated with increased seizure risk, particularly in cardiac surgery 1

Consider administering the first 1g loading dose en route to the hospital to ensure treatment within the critical 3-hour window 1
Pre-hospital administration should be incorporated into bleeding management protocols 1
Administer to ALL trauma patients with significant bleeding or at risk of significant hemorrhage 1
Do not restrict to only "massive hemorrhage" protocols - only 40% of preventable deaths occur in the highest-risk group 1

Never delay TXA administration beyond 3 hours - this converts benefit to harm 1
Do not restrict use to only massive transfusion protocols - broader application prevents more deaths 1
Do not use alternative routes without IV access - current guidelines only support IV administration based on CRASH-2 evidence 4
Do not use higher doses than the CRASH-2 protocol - this increases seizure risk without proven additional benefit 1

The CRASH-2 trial demonstrated exceptional cost-effectiveness across all economic settings, with incremental cost per life-year gained of $48 in Tanzania, $66 in India, and $64 in the UK 1